Skip to main content
Top
Published in: Critical Care 1/2019

Open Access 01-12-2019 | Septicemia | Research

The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort

Authors: Eleni Karakike, Evdoxia Kyriazopoulou, Iraklis Tsangaris, Christina Routsi, Jean-Louis Vincent, Evangelos J. Giamarellos-Bourboulis

Published in: Critical Care | Issue 1/2019

Login to get access

Abstract

Background

Since the Sepsis-3 criteria, change in Sequential Organ Failure Assessment (SOFA) score has become a key component of sepsis identification. Thus, it could be argued that reversal of this change (ΔSOFA) may reflect sepsis response and could be used as measure of efficacy in interventional trials. We aimed to assess the predictive performance of ΔSOFA for 28-day mortality.

Methods

Data from two previously published randomized controlled trials were studied: the first reporting on patients with severe Gram-negative infections as a derivation cohort and the second reporting on patients with ventilator-associated pneumonia as a validation cohort. Only patients with sepsis according to the Sepsis-3 definition were included in this analysis. SOFA scores were calculated on days 1, 2, 3, 5, 7, 14, and 28.

Results

We included 448 patients within the derivation cohort and 199 within the validation cohort. Mean SOFA scores on day 1 were 6.06 ± 4.07 and 7.84 ± 3.39, and 28 day mortality 22.8% and 29.6%, respectively. In the derivation cohort, the earliest time point where ΔSOFA score predicted mortality was day 7 (AUROC (95% CI) 0.84 (0.80–0.89); p < 0.001). The best tradeoff for prediction was found with 25% changes (78% sensitivity, 80% specificity); less than 25% decrease of admission SOFA was associated with increased mortality (odds ratio for death 14.87). This finding was confirmed in the validation cohort.

Conclusions

ΔSOFA on day 7 is a useful early prognostic marker of 28-day mortality and could serve as an endpoint in future sepsis trials alongside mortality.

Trial registration

ClinicalTrials.​gov numbers NCT01223690 and NCT00297674
Appendix
Available only for authorised users
Literature
1.
go back to reference Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055–64.CrossRef Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055–64.CrossRef
2.
go back to reference Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41:975–84.CrossRef Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41:975–84.CrossRef
3.
go back to reference Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358:111–24.CrossRef Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358:111–24.CrossRef
4.
go back to reference Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372:1301–11.CrossRef Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372:1301–11.CrossRef
5.
go back to reference Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–77.CrossRef Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–77.CrossRef
7.
go back to reference U. S. Food Drug Administration F. Guidance for industry: community-acquired bacterial pneumonia: developing drugs for treatment, Center for Drug Evaluation and Research. Silver Spring: Food and Drug Administration, US Department of Health and Human Services; 2014. Accessed 15 Nov 2017. U. S. Food Drug Administration F. Guidance for industry: community-acquired bacterial pneumonia: developing drugs for treatment, Center for Drug Evaluation and Research. Silver Spring: Food and Drug Administration, US Department of Health and Human Services; 2014. Accessed 15 Nov 2017.
8.
go back to reference Foundation for the National Institutes of Health Biomarkers Consortium HABP/VABP Working Group, 2013. Interim considerations for clinical trial design for the study of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Submission to Docket FDA-2013-N-0556. https://http://www.pharmamedtechbi.com/~/media/Supporting Documents/The Pink Sheet/75/36/fnihcommentsantibacterial.pdf. Accessed 15 Nov 2017. Foundation for the National Institutes of Health Biomarkers Consortium HABP/VABP Working Group, 2013. Interim considerations for clinical trial design for the study of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Submission to Docket FDA-2013-N-0556. https://http://​www.​pharmamedtechbi.​com/​~/​media/​Supporting Documents/The Pink Sheet/75/36/fnihcommentsantibacterial.pdf. Accessed 15 Nov 2017.
9.
go back to reference Talbot GH, Powers JH, Hoffmann SC, Biomarkers Consortium of the Foundation for the National Institutes of Health C-A, Teams H-VP. Developing outcomes assessments as endpoints for registrational clinical trials of antibacterial drugs: 2015 update from the biomarkers consortium of the foundation for the national institutes of health. Clin Infect Dis. 2016;62:603–7.CrossRef Talbot GH, Powers JH, Hoffmann SC, Biomarkers Consortium of the Foundation for the National Institutes of Health C-A, Teams H-VP. Developing outcomes assessments as endpoints for registrational clinical trials of antibacterial drugs: 2015 update from the biomarkers consortium of the foundation for the national institutes of health. Clin Infect Dis. 2016;62:603–7.CrossRef
10.
go back to reference Prescott HC, Osterholzer JJ, Langa KM, Angus DC, Iwashyna TJ. Late mortality after sepsis: propensity matched control study. BMJ. 2016;353:i2375.CrossRef Prescott HC, Osterholzer JJ, Langa KM, Angus DC, Iwashyna TJ. Late mortality after sepsis: propensity matched control study. BMJ. 2016;353:i2375.CrossRef
11.
go back to reference Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–55.CrossRef Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–55.CrossRef
12.
go back to reference Giamarellos-Bourboulis EJ, Mylona V, Antonopoulou A, Tsangaris I, Koutelidakis I, Marioli A, et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. J Antimicrob Chemother. 2014;69:1111–8.CrossRef Giamarellos-Bourboulis EJ, Mylona V, Antonopoulou A, Tsangaris I, Koutelidakis I, Marioli A, et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. J Antimicrob Chemother. 2014;69:1111–8.CrossRef
13.
go back to reference Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, Plachouras D, Kollias S, Raftogiannis M, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis. 2008;46:1157–64.CrossRef Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, Plachouras D, Kollias S, Raftogiannis M, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis. 2008;46:1157–64.CrossRef
14.
go back to reference Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: a systematic review. Crit Care. 2008;12:R161.CrossRef Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: a systematic review. Crit Care. 2008;12:R161.CrossRef
15.
go back to reference Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286:1754–8.CrossRef Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286:1754–8.CrossRef
16.
go back to reference Soo A, Zuege DJ, Fick GH, Niven DJ, Berthiaume LR, Stelfox HT, et al. Describing organ dysfunction in the intensive care unit: a cohort study of 20,000 patients. Crit Care. 2019;23:186.CrossRef Soo A, Zuege DJ, Fick GH, Niven DJ, Berthiaume LR, Stelfox HT, et al. Describing organ dysfunction in the intensive care unit: a cohort study of 20,000 patients. Crit Care. 2019;23:186.CrossRef
17.
go back to reference de Grooth HJ, Geenen IL, Girbes AR, Vincent JL, Parienti JJ, Oudemans-van Straaten HM. SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care. 2017;21:38.CrossRef de Grooth HJ, Geenen IL, Girbes AR, Vincent JL, Parienti JJ, Oudemans-van Straaten HM. SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care. 2017;21:38.CrossRef
18.
go back to reference Iba T, Arakawa M, Mochizuki K, Nishida O, Wada H, Levy JH. Usefulness of measuring changes in SOFA score for the prediction of 28-day mortality in patients with sepsis-associated disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2019;25:1076029618824044.CrossRef Iba T, Arakawa M, Mochizuki K, Nishida O, Wada H, Levy JH. Usefulness of measuring changes in SOFA score for the prediction of 28-day mortality in patients with sepsis-associated disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2019;25:1076029618824044.CrossRef
19.
go back to reference de Azevedo JR, Torres OJ, Beraldi RA, Ribas CA, Malafaia O. Prognostic evaluation of severe sepsis and septic shock: procalcitonin clearance vs delta sequential organ failure assessment. J Crit Care. 2015;30(219):e9–12. de Azevedo JR, Torres OJ, Beraldi RA, Ribas CA, Malafaia O. Prognostic evaluation of severe sepsis and septic shock: procalcitonin clearance vs delta sequential organ failure assessment. J Crit Care. 2015;30(219):e9–12.
20.
go back to reference Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med. 2016;375:1638–48.CrossRef Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med. 2016;375:1638–48.CrossRef
21.
go back to reference Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, et al. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA. 2012;307:2390–9.CrossRef Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, et al. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA. 2012;307:2390–9.CrossRef
Metadata
Title
The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort
Authors
Eleni Karakike
Evdoxia Kyriazopoulou
Iraklis Tsangaris
Christina Routsi
Jean-Louis Vincent
Evangelos J. Giamarellos-Bourboulis
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2019
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-019-2665-5

Other articles of this Issue 1/2019

Critical Care 1/2019 Go to the issue